Region: Global
Category: Life Sciences

Global Life Sciences

(45,027 reports matching your criteria)
  • Prescription Drugs

    ... CAGR of 5.7% over the analysis period 2024-2030. Generic Drugsone of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$498.0 Billion by the end of the analysis period. ... Read More

  • Carotenoids

    ... 3.8% over the analysis period 2024-2030. Beta-Carotene, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in ... Read More

  • Anti-Obesity Drugs

    ... CAGR of 8.7% over the analysis period 2024-2030. Prescription Drugs, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$4.9 Billion by the end of the analysis ... Read More

  • Medical Membranes

    ... CAGR of 7.7% over the analysis period 2024-2030. Ultrafiltration Technology, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More

  • Vascular Grafts

    ... CAGR of 7.2% over the analysis period 2024-2030. Endovascular Aneurysm Repair (EVAR) Indication, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$2.6 Billion by the end ... Read More

  • Orthopedic Braces & Support, Casting and Splints

    ... expected to reach US$10.1 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Orthopedic Braces & Supports, one of the segments analyzed in the report, is expected to record a ... Read More

  • Surgical Gloves

    ... CAGR of 6.6% over the analysis period 2024-2030. Nitrile Gloves, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$2.4 Billion by the end of the analysis ... Read More

  • Humanized Mouse and Rat Model

    ... Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Humanized Rat Models, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$13.6 ... Read More

  • Hybrid Operating Rooms

    ... at a CAGR of 12.2% over the analysis period 2024-2030. Intraoperative Diagnostic Imaging Systems, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$1.3 Billion by the ... Read More

  • Cosmetic Antioxidants

    ... CAGR of 5.0% over the analysis period 2024-2030. Vitamins, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$54.2 Million by the end of the analysis period. ... Read More

  • Genotyping

    ... 15.3% over the analysis period 2024-2030. Polymerase Chain Reaction (PCR) Technology, one of the segments analyzed in the report, is expected to record a 15.9% CAGR and reach US$10.9 Billion by the end of the ... Read More

  • Healthcare Mobility Solutions

    ... at a CAGR of 18.9% over the analysis period 2024-2030. Mobile Devices, one of the segments analyzed in the report, is expected to record a 17.6% CAGR and reach US$120.5 Billion by the end of ... Read More

  • Hemodialysis

    ... 4.7% over the analysis period 2024-2030. Hemodialysis Services, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$80.1 Billion by the end of the analysis period. Growth ... Read More

  • Hemophilia Drugs

    ... CAGR of 5.5% over the analysis period 2024-2030. Hemophilia A Drugs, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$21.3 Billion by the end of the ... Read More

  • Herpes Marker Testing

    ... at a CAGR of 4.9% over the analysis period 2024-2030. Antibody / Antigen-Based Kits, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$332.9 Million by the ... Read More

  • High Pressure Pumps

    ... at a CAGR of 3.5% over the analysis period 2024-2030. Dynamic Pumps, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.0 Billion by the end of ... Read More

  • Hemodialysis Catheters

    ... CAGR of 4.2% over the analysis period 2024-2030. Cuffed Tunneled Catheters, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$542.7 Million by the end of the ... Read More

  • Hepatitis B Vaccines

    ... at a CAGR of 4.4% over the analysis period 2024-2030. Combination Vaccines, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.6 Billion by the end of ... Read More

  • Cell Dissociation

    ... CAGR of 11.6% over the analysis period 2024-2030. Enzymatic Dissociation Products, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$506.9 Million by the end of the ... Read More

  • Cell Expansion

    ... CAGR of 14.8% over the analysis period 2024-2030. Cell Expansion Consumables, one of the segments analyzed in the report, is expected to record a 16.0% CAGR and reach US$42.4 Billion by the end of the ... Read More

  • Cervical Cancer Diagnostic Testing

    ... 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Pap Smear Test, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$5.3 Billion by ... Read More

  • Chiral Chemicals

    ... CAGR of 6.2% over the analysis period 2024-2030. Traditional Separation Method, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$50.8 Billion by the end of the ... Read More

  • Clot Management Devices

    ... at a CAGR of 4.6% over the analysis period 2024-2030. Percutaneous Thrombectomy Devices, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.1 Billion by the end ... Read More

  • Cold Pressed Juices

    ... at a CAGR of 5.6% over the analysis period 2024-2030. Organic Cold Pressed Juices, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$2.3 Billion by the ... Read More

  • In-Vitro Colorectal Cancer Screening Tests

    ... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach ... Read More

Research Assistance

Live help

Join Alert Me Now!

Sign Up

Find out more on our blog
Cookie Settings